NEW YORK – An age-old problem with the business-as-usual model in the biotech market is that the objectives of the principal stakeholders are integrally at odds with one another. The executives, investors and researchers who make things happen in the drug development world all want to see their drugs approved or they want to experience an exit strategy come to fruition, but they have different ideologies on achieving that goal.